Clinical Trials

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06578247 2026-03-31

QuANTUM-WILD

Phase 3 Recruiting

700 enrolled

Phase 2 Active not recruiting

Leukemia, Leukemia, Myeloid, Acute

NCT03591510 2026-03-13

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

22 enrolled

Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Phase 1 Recruiting

420 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

NCT07255872 2026-03-05

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Phase 2/3 Not yet recruiting

216 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03860844 2025-09-09

ISAKIDS

Phase 2 Terminated

67 enrolled 25 charts

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02303821 2025-06-04

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

141 enrolled 37 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02632708 2025-04-11

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Phase 1 Active not recruiting

153 enrolled

Leukemia, Myeloid, Acute

NCT02834390 2025-03-05

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

7 enrolled 16 charts

Neoplasms, Leukemia, Myeloid, Acute

NCT02038777 2025-02-26

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

48 enrolled 85 charts

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04778397 2025-02-05

ENHANCE-2

Phase 3 Terminated

258 enrolled 25 charts

Leukemia, Myeloid, Acute

NCT02236013 2024-11-05

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

80 enrolled

Leukemia, Myeloid, Acute

NCT02668653 2024-08-06

QuANTUM-First

539 enrolled 20 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

111 enrolled 23 charts 2 FDA

LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03379727 2024-02-29

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

301 enrolled 9 charts

Phase 3 Not yet recruiting

Leukemia, Myeloid, Acute

NCT06182592 2023-12-28

A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

120 enrolled

Neoplasm Metastasis, Leukemia, Myeloid, Acute

NCT03298984 2023-11-15

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

32 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT03416179 2023-04-21

BRIGHT AML1019

730 enrolled 35 charts

Leukemia, Myeloid, Acute

NCT04402723 2022-12-01

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

8 enrolled

Leukemia, Myeloid, Acute

NCT03850535 2022-06-21

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Phase 1/2 Terminated

24 enrolled 14 charts

Leukemia, Myeloid, Acute

NCT03563560 2022-04-12

AML

10 enrolled

Leukemia, Myeloid, Acute

NCT00093600 2020-12-19

PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

69 enrolled

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01696084 2020-08-10

301

309 enrolled 14 charts 2 FDA

Leukemia, Myeloid, Acute

NCT03135028 2020-03-06

Japanese AML

9 enrolled 10 charts

255 enrolled 82 charts 2 FDA

Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01546038 2020-03-03

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Phase 1/2 Withdrawn

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT02954653 2019-11-21

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

8 enrolled 13 charts

Recurrence, Leukemia, Myeloid, Acute

NCT02343939 2019-11-15

ENTO in AML

Phase 1/2 Terminated

148 enrolled 26 charts

Classical hematologyOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01890746 2019-09-11

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Phase 2 Completed

148 enrolled 42 charts

Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT01390337 2019-02-12

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

19 enrolled

Leukemia, Myeloid, Acute

NCT02326584 2018-05-09

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

116 enrolled

Leukemia, Myeloid, Acute

NCT00788892 2018-01-12

Trial of CPX-351 in Newly Diagnosed Elderly AML Patients

Phase 2 Completed

126 enrolled 12 charts

Disease, Leukemia, Leukemia, Myeloid, Acute

NCT01773408 2017-01-25

A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia

122 enrolled

Leukemia, Myeloid, Acute

NCT01265199 2013-01-23

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

29 enrolled

Leukemia, Myeloid, Acute

NCT00715637 2010-10-13

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Phase 3 Unknown

420 enrolled

Leukemia, Lymphatic Diseases

NCT00129168 2008-04-01

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

100 enrolled

Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute

NCT00002093 2005-06-24

A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.